The combination of dolutegravir and lamivudine is effective for treatment-naive patients regardless of age, gender, or race, according to a new subgroup analysis of the GEMINI clinical studies.
Gilead Sciences is working with the federal government to roll out its pre-exposure prophylaxis (PrEP) donation program. Here, we detail what we know so far about how this will be implemented.
Black Women in Atlanta Need More PrEP Access. Researchers and Advocates Are Working to Make This a Reality.
While most pre-exposure prophylaxis (PrEP) campaigns focus on gay and bisexual men, Fulton County Board of Health officials and advocates look for solutions to get PrEP to black women.
If everyone living with HIV gets into care, do we have enough providers to support them? HIV doctors are proposing policy changes to address the workforce shortage.
A series of studies aim to determine whether test-and-treat strategies can be implemented for people with hepatitis C, much like programs for people living with HIV.
Grindr Users Take PrEP More and Have Lower HIV Rates, but Have Higher Rate of STIs Than Men Not on the App
Gay and bisexual men who used Grindr were having more sex acts associated with increased risk, but were more likely to use PrEP or be open to it, which translated to lower HIV incidence.
At IDWeek in Washington, D.C., leading infectious disease doctors and researchers met with U.S. Congress leadership to discuss HIV prevention, treatment, and care policy.
We're covering the latest news and research from this major interdisciplinary meeting on infectious diseases, which takes place in Washington, D.C., from Oct. 2 to Oct. 6.
With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.
Delstrigo, a fixed-dose combination regimen containing the newly approved antiretroviral doravirine (Pifeltro), lamivudine (3TC, Epivir), and tenofovir disoproxil fumarate (Viread), was non-inferior to other triple combination therapies in participan...